Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Mahmoud Yacout, Bahga Katamesh, Yazan Jabban, Rong He, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Abhishek A. Mangaonkar, Mithun V Shah, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2024-208957

Published: 2024

Journal Articles

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2024-204114

Published: 2024

Journal Articles

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Anuya A. Natu, Clifford M. Csizmar, Terra L. Lasho, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2024-209236

Published: 2024

Journal Articles

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Talha Badar, Kashish J. Shah, Mobachir El Kettani, James M. Foran, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Naseema Gangat, Aref Al-Kali, Mithun V Shah, Hassan B Alkhateeb, Antoine N. Saliba, William J. Hogan, Cecilia Y. Arana Yi, Lisa Sproat, Jeanne Palmer, Mark R. Litzow, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2024-203825

Published: 2024

Journal Articles

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Blood (2024) 144 (Supplement 1): 1820.

https://doi.org/10.1182/blood-2024-209193

Published: 2024

Journal Articles

Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53 -Mutated Acute Myeloid Leukemia

Clifford M. Csizmar, Antoine N. Saliba, Kevin L. Peterson, Xue Wei Meng, B. Douglas Smith, Gabriel Ghiaur, Mrinal M. Patnaik, Scott H. Kaufmann

Blood (2024) 144 (Supplement 1): 5782.

https://doi.org/10.1182/blood-2024-208583

Published: 2024

Journal Articles

Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis

Ayalew Tefferi, Chandra Hutchens, Antoine N. Saliba, Giuseppe Gaetano Loscocco, Kebede Begna, William J. Hogan, Kaaren K. Reichard, Animesh D. Pardanani, Sima Bhatt, William Savage, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2024-209070

Published: 2024

Journal Articles

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Clifford M. Csizmar, Anuya A. Natu, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Sanam Loghavi, Alexandre Bazinet, Terra L. Lasho, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 6747.

https://doi.org/10.1182/blood-2024-209126

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Yazan Jabban, Rong He, Kurt Bessonen, Patricia Greipp, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, Aasiya Matin, William J. Hogan, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Mithun V Shah, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 6700.

https://doi.org/10.1182/blood-2024-201128

Published: 2024

Journal Articles

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Nadia Toumeh, Yazan Jabban, Ahmad Nanaa, Rong He, David Viswanatha, Dragan Jevremovic, James M. Foran, Cecilia Y. Arana Yi, Antoine N. Saliba, Mehrdad Hefazi, William J. Hogan, Mithun V Shah, Abhishek A. Mangaonkar, Mrinal M. Patnaik, Hassan B Alkhateeb, Aref Al-Kali

Blood (2024) 144 (Supplement 1): 2869.

https://doi.org/10.1182/blood-2024-209413

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

How I treat non-transfusion-dependent β-thalassemia

Antoine N. Saliba, Khaled M. Musallam, Ali T. Taher

Blood (2023) 142 (11): 949–960.

https://doi.org/10.1182/blood.2023020683

Published: 2023

Includes: Supplemental data

Journal Articles

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Clifford M. Csizmar, Antoine N. Saliba, Mark R. Litzow, Naseema Gangat, Aref Al-Kali, James M. Foran, William J. Hogan, Jeanne M. Palmer, Abhishek A. Mangaonkar, Kirsten McCullough, Ayalew Tefferi, Hassan B. Alkhateeb, Mrinal M.M. Patnaik

Blood (2022) 140 (Supplement 1): 12238–12240.

https://doi.org/10.1182/blood-2022-165470

Published: 2022

Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 6058–6060.

https://doi.org/10.1182/blood-2022-163795

Published: 2022

Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 1435–1437.

https://doi.org/10.1182/blood-2022-167731

Published: 2022

Journal Articles

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Antoine N Saliba, MD, H. Scott Boswell, MD, Larry D Cripe, MD, Mohammad Issam Abu Zaid, MBBS, Jill Weisenbach, RN, OCN, Hamid Sayar, MD MSc

Blood (2017) 130 (Supplement 1): 3897.

https://doi.org/10.1182/blood.V130.Suppl_1.3897.3897

Published: 2017

Journal Articles

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Ali Amid, MD, Rebecca Leroux, BScN, Manuela Merelles-Pulcini, MSc, Saeed Yassobi, MD, Antoine N Saliba, MD, Richard Ward, MSc, MRCP, FRCPath, Mehran Karimi, MD, Ali T. Taher, MD PhD, Robert J Klaassen, MD, Melanie Kirby-Allen, MD

Blood (2016) 128 (22): 3633.

https://doi.org/10.1182/blood.V128.22.3633.3633

Published: 2016

NARROW

A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations

Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Decitabine Synergizes with Replication Checkpoint Inhibitors in TP53 -Mutated Acute Myeloid Leukemia

Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Clinical Characteristics and Prognostic Significance of Co-Mutated SETBP1 / GATA2 Myeloid Neoplasms

Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

How I treat non-transfusion-dependent β-thalassemia

Response Rates to Venetoclax Based Therapies in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only